IDRx
IDRx, Inc. is a clinical-stage biopharmaceutical company focused on developing precision therapies for cancer treatment. Their lead product candidate, IDRX-42, is a potent KIT inhibitor targeting GIST, aiming to overcome treatment resistance and adverse events of existing therapies. The company is advancing IDRX-42 through clinical trials.
Buy Funded Startups lists
Funding Round: Series B
Funding Amount: $120M
Date: 07-Aug-2024
Investors: RA Capital Management, Commodore Capital, Blackstone Multi-Asset Investing, Rock Springs Capital, a U.S.-based healthcare-focused fund, Andreessen Horowitz (a16z) Bio + Health, Casdin Capital, Nextech Invest Ltd., Forge Life Science Partners, Nick Lydon, Merck KGaA
Markets: Biotechnology, Oncology, Pharmaceuticals, Life Science, Product Research
HQ: Plymouth, Massachusetts, United States
Founded: 2021
Website: https://www.idrx.com/
LinkedIn: https://www.linkedin.com/company/idrx/about
Crunchbase: https://www.crunchbase.com/organization/idrx
Leave a Comment
Comments
No comments yet.